Drug Profile

DNL 201

Alternative Names: DNL-201

Latest Information Update: 28 May 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Genentech
Developer Denali Therapeutics Inc
Class Antiparkinsonians; Small molecules
Mechanism of Action LRRK2 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Parkinson's disease

Most Recent Events

28 May 2023 No recent reports of development identified for phase-I development in Parkinson's-disease in USA (PO)
26 Feb 2021 Phase-I development in Parkinson's-disease is still ongoing in USA (PO)
26 Feb 2021 Pharmacodynamics and adverse events data from a phase Ib trial in Parkinson's disease released by Denali Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com